Skip to main content

A single-arm, multi-center, open-label proof of concept safety and efficacy study of FCR001 cell-based therapy in adults with rapidly progressive diffuse cutaneous systemic sclerosis at risk for organ failure

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Rheumatology and Immunology

Awarded By

Talaris Therapeutics

Start Date

February 28, 2023

End Date

February 27, 2028
 

Administered By

Medicine, Rheumatology and Immunology

Awarded By

Talaris Therapeutics

Start Date

February 28, 2023

End Date

February 27, 2028